SCHEMBL3230449

SCHEMBL3230449

CN1CCN(c2ccccc2)c2ccc(-c3ccc4nncn4c3)cc2C1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.40
DNMT1 P26358 1/20 0.37
SCN5A Q14524 1/20 0.36
BACE1 P56817 1/20 0.33
LRRK2 Q5S007 2/20 0.32
MAPK14 Q16539 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
DPP4 P27487 1/20 0.31
SRD5A1 P18405 1/20 0.31
MGLL Q99685 1/20 0.30
HRH4 Q9H3N8 1/20 0.30
BRD4 O60885 1/20 0.30
BRD2 P25440 1/20 0.30
BRD3 Q15059 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227458 0.90 SCN9A (0.41) SCN9ADNMT1SCN5ABACE1MAPK14
SCHEMBL3231098 0.90 SCN9A (0.39) SCN9ADNMT1SCN5ABACE1MAPKAPK2
SCHEMBL3232437 0.89 SCN9A (0.40) SCN9ADNMT1SCN5ABACE1LRRK2
SCHEMBL3227365 0.89 SCN9A (0.40) SCN9ADNMT1SCN5ABACE1MAPK14
SCHEMBL3234016 0.88 SCN9A (0.37) SCN9ADNMT1SCN5ABACE1LRRK2
SCHEMBL3229280 0.87 SCN5A (0.36) SCN9ADNMT1SCN5ABACE1LRRK2
SCHEMBL3224973 0.86 SCN9A (0.38) SCN9ADNMT1SCN5ABACE1LRRK2
SCHEMBL3235613 0.86 SLC6A2 (0.38) SCN9ADNMT1SCN5ABACE1HRH4
SCHEMBL3236761 0.79 DYRK1A (0.43) SCN9ASCN5ALRRK2MAPK14
SCHEMBL3227496 0.77 SCN9A (0.48) SCN9AMAPK14MAPKAPK2SRD5A1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885DNMT1 1607/4885SCN5A 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.